Stockreport

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024 [Y...

Cardiol Therapeutics Inc. - Class A Common Shares  (CRDL) 
PDF Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL TSX: CRDL Cardiol " or the " Company "), a clinical-stage life scienc [Read more]